当前蛋白身份:Q13164 重新检索
本组结构的主要差异维度
构建体不同 突变/修饰不同 组装状态不同 配体/离子不同 实验环境不同 结构质量指标不同

差异标签只比较当前检索结果;所有PDB和assembly原始记录仍分别保留。

相关结构差异明细

一行代表一个 PDB 条目中的一个 biological assembly;同一蛋白的多个单体会分别列出。

PDB 条目 Assembly / 聚集状态 构建体 突变与修饰 配体、离子与非聚合物 实验方法 实验环境 结构质量
2Q8Y Structural insight into the enzymatic mechanism of the phophothreonine lyase 提交 2007-06-12 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 214–222(9 aa)
非标准单体:是(mmCIF未提供具体位点) 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 6;293 K;12% PEG3350,0.1M MES pH6.0,0.1 M NaKTartrate, VAPOR DIFFUSION, HANGING DROP, temperature 293K
分辨率 2.00 Å R-free 0.217
4B99 Crystal Structure of MAPK7 (ERK5) with inhibitor 提交 2012-09-03 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 1–397(397 aa) 片段:KINASE DOMAIN
未记录 R4L 11-cyclopentyl-2-[[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]carbonyl-phenyl]amino]-5-methyl-pyrimido[4,5-b][1,4]benzodiazepin-6-one × 1 X-RAY DIFFRACTION
X-ray结晶条件 pH 6;0.05M CACL2, 0.1M MES PH 6.0, 20% PEG 6000, 10% ETHYLENE GLYCOL
分辨率 2.80 Å R-free 0.287
4IC7 Crystal structure of the ERK5 kinase domain in complex with an MKK5 binding fragment 提交 2012-12-10 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 1–431(431 aa)
未记录 ANP PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 6.5;296 K;48% PEG 200, 100mM MIB, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 296K
分辨率 2.60 Å R-free 0.258
4IC7 Crystal structure of the ERK5 kinase domain in complex with an MKK5 binding fragment 提交 2012-12-10 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 1–431(431 aa)
未记录 ANP PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 6.5;296 K;48% PEG 200, 100mM MIB, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 296K
分辨率 2.60 Å R-free 0.258
4IC8 Crystal structure of the apo ERK5 kinase domain 提交 2012-12-10 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 1–431(431 aa)
未记录 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 4.5;296 K;30% PEG 200, 100mM MIB, pH 4.5, VAPOR DIFFUSION, SITTING DROP, temperature 296K
分辨率 2.80 Å R-free 0.290
4IC8 Crystal structure of the apo ERK5 kinase domain 提交 2012-12-10 Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 B 1–431(431 aa)
未记录 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 4.5;296 K;30% PEG 200, 100mM MIB, pH 4.5, VAPOR DIFFUSION, SITTING DROP, temperature 296K
分辨率 2.80 Å R-free 0.290
4ZSG MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR 提交 2015-05-13 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 47–393(347 aa) 片段:residues 47-393
未记录 GOL GLYCEROL × 5 4QX 3-amino-5-[(4-chlorophenyl)amino]-N-(propan-2-yl)-1H-1,2,4-triazole-1-carboxamide × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 6.25;293 K;4-6 % w/v PEG 6000, 0.1 M MES, 5 mM DTT
分辨率 1.79 Å R-free 0.235
4ZSJ MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR 提交 2015-05-13 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 50–393(344 aa) 片段:UNP residues 50-393
未记录 GOL GLYCEROL × 4 4R0 3-amino-5-[(4-chloro-3-methylphenyl)amino]-N-(propan-2-yl)-1H-1,2,4-triazole-1-carboxamide × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 6.25;293 K;4-6 % w/v PEG 6000, 0.1 M MES, 5 mM DTT
分辨率 2.48 Å R-free 0.230
4ZSL MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR 提交 2015-05-13 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 53–393(341 aa) 片段:UNP residues 53-393
未记录 4QZ 3-amino-5-[(4-chlorophenyl)amino]-N-[(1S)-1-phenylethyl]-1H-1,2,4-triazole-1-carboxamide × 1 GOL GLYCEROL × 5 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 6.25;297 K;4-6 % w/v PEG 6000, 0.1 M MES, 5 mM DTT
分辨率 2.25 Å R-free 0.219
5BYY ERK5 IN COMPLEX WITH SMALL MOLECULE 提交 2015-06-11 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 49–394(346 aa) 片段:KINASE DOMAIN, unp residues 49-394
未记录 4WG 2-{[2-ethoxy-4-(4-hydroxypiperidin-1-yl)phenyl]amino}-5,11-dimethyl-5,11-dihydro-6H-pyrimido[4,5-b][1,4]benzodiazepin-6-one × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;293 K;0.01 M Tris 8.50 0.01 M MgCl2 13 % PEG4000 0.18 M Na-formiate 0.10 M MES, pH=6.50
分辨率 2.79 Å R-free 0.273
5BYZ ERK5 in complex with small molecule 提交 2015-06-11 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 48–395(348 aa) 片段:KINASE DOMAIN, unp residues 48-395
未记录 4WE 4-({5-fluoro-4-[2-methyl-1-(propan-2-yl)-1H-imidazol-5-yl]pyrimidin-2-yl}amino)-N-[2-(piperidin-1-yl)ethyl]benzamide × 1 GOL GLYCEROL × 6 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;277 K;11 % PEG4000 0.01 M MgCl2 0.18 M Na-Formiate 0.10 M MES, pH=6.50 0.01 M Tris/Cl, pH=8.50
分辨率 1.65 Å R-free 0.192
5O7I ERK5 in complex with a pyrrole inhibitor 提交 2017-06-08 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 46–402(357 aa) 片段:UNP residues 46-402
未记录 9N8 4-(2-bromanyl-6-fluoranyl-phenyl)carbonyl-~{N}-pyridin-3-yl-1~{H}-pyrrole-2-carboxamide × 1 DMS DIMETHYL SULFOXIDE × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 6.5;293 K;5 % (v/v) PEG 6000, 0.1 M MES (pH 6.0), 5 mM DTT
分辨率 2.38 Å R-free 0.220
6HKM Crystal structure of Compound 1 with ERK5 提交 2018-09-07 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 49–395(347 aa) 片段:KINASE DOMAIN
未记录 G92 [4-(6,7-dimethoxyquinazolin-4-yl)piperidin-1-yl]-[4-(trifluoromethyloxy)phenyl]methanone × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;293 K;11% PEG 4000, 100mM MgCl2, 160mM sodium formate, 100mM MES pH 6.75, 10mM Tris pH 8.5
分辨率 2.47 Å R-free 0.280
6HKN Crystal structure of Compound 35 with ERK5 提交 2018-09-07 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 54–393(340 aa) 片段:KINASE DOMAIN
未记录 G9E [2-azanyl-4-(trifluoromethyloxy)phenyl]-[4-(7-methoxyquinazolin-4-yl)piperidin-1-yl]methanone × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;293 K;15% PEG 4000, 100mM MgCl2, 180mM Sodium formate, 100 mM MES pH 6.5, 10mM Tris pH 8.0
分辨率 2.33 Å R-free 0.249
7PUS ERK5 in complex with Pyrrole Carboxamide scaffold 提交 2021-09-30 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 AAA 46–402(357 aa) 片段:UNP residues 46-402
未记录 86E 4-[3,6-bis(chloranyl)-2-fluoranyl-phenyl]carbonyl-~{N}-(1-methylpyrazol-4-yl)-1~{H}-pyrrole-2-carboxamide × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;293 K;5 % (V/V) PEG 6000, 0.1 M MES (PH 6.0), 5 MM DTT
分辨率 2.59 Å R-free 0.285
9LTA Crystal Structure of Compound SKLB-D18 with MAPK7 (ERK5) 提交 2025-02-05 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 B 48–393(346 aa)
未记录 A1EKR 4-[5-chloranyl-2-[[3-[(dimethylamino)methyl]phenyl]amino]pyrimidin-4-yl]-~{N}-morpholin-4-yl-thiophene-2-carboxamide × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;277 K;0.1M Hepes 7.5, 10% PEG4K, 7% isopropanol
分辨率 2.33 Å R-free 0.292
9LTA Crystal Structure of Compound SKLB-D18 with MAPK7 (ERK5) 提交 2025-02-05 Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 48–393(346 aa)
未记录 A1EKR 4-[5-chloranyl-2-[[3-[(dimethylamino)methyl]phenyl]amino]pyrimidin-4-yl]-~{N}-morpholin-4-yl-thiophene-2-carboxamide × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;277 K;0.1M Hepes 7.5, 10% PEG4K, 7% isopropanol
分辨率 2.33 Å R-free 0.292